Chi SuHyuk, Ko Jeong-Kyung, Kang June, Gim Jeong-An, Lee Moon-Soo
Department of Psychiatry, Korea University Guro Hospital, Seoul, Korea.
Department of Brain and Cognitive Engineering, Korea University, Seoul, Korea.
Clin Psychopharmacol Neurosci. 2025 Aug 31;23(3):411-417. doi: 10.9758/cpn.24.1266. Epub 2025 Mar 5.
This study aims to explore the relationship between symptom severity and cytokine levels in patients with tic disorders by evaluating these parameters at baseline and after a one-year follow-up.
A total of 44 tic disorder patients were recruited, 35 completed baseline assessments, and 20 completed endpoint assessments after one year. Based on changes in Yale Global Tic Severity Scale scores, patients were categorized into 'improved' and 'persistent' groups. Cytokine levels were measured using a Luminex human cytokine multiplex assay at both time points.
Significant increases were found in interferon (IFN)-α2, IFN-γ, interleukin (IL)-1β, IL-6, IL-10, IL-12 p40, IL-12 p70, and IL-13, while IL-1ra and IL-4 levels decreased. Changes in IFN-γ levels showed significant correlations with tic severity, with higher endpoint levels being linked to symptom worsening. Baseline IL-5 levels were significantly higher in the improved group compared to the persistent group.
This study underscores the potential of IFN-γ and IL-5 as biomarkers and therapeutic targets in tic disorders. The findings suggest that these cytokines could be instrumental in assessing tic disorder severity and developing targeted therapies. Further research involving larger cohorts is needed to validate these findings and explore cytokine-targeted therapies for tic disorders.
本研究旨在通过在基线和一年随访后评估这些参数,探讨抽动障碍患者症状严重程度与细胞因子水平之间的关系。
共招募44例抽动障碍患者,35例完成基线评估,20例在一年后完成终点评估。根据耶鲁全球抽动严重程度量表评分的变化,将患者分为“改善”组和“持续”组。在两个时间点均使用Luminex人细胞因子多重检测法测量细胞因子水平。
发现干扰素(IFN)-α2、IFN-γ、白细胞介素(IL)-1β、IL-6、IL-10、IL-12 p40、IL-12 p70和IL-13显著升高,而IL-1ra和IL-4水平降低。IFN-γ水平的变化与抽动严重程度显著相关,终点水平越高与症状恶化相关。改善组的基线IL-5水平显著高于持续组。
本研究强调了IFN-γ和IL-5作为抽动障碍生物标志物和治疗靶点的潜力。研究结果表明,这些细胞因子可能有助于评估抽动障碍的严重程度并开发靶向治疗方法。需要进一步开展涉及更大队列的研究来验证这些发现,并探索针对抽动障碍的细胞因子靶向治疗方法。